source
- ICER finds AstraZeneca’s blood pressure pill Baxfendy not cost-effective at $10,950 a yearICER released a report saying the clinical benefits of AstraZeneca’s new blood pressure medication Baxfendy do not justify its listed price. The agency noted the drug is priced at $10,950 per pati…
- Redx Pharma pursues new reverse merger with Skye after 2023 setbackRedx Pharma, a UK biotech focused on ROCK inhibitor therapies for fibrosis, is seeking a reverse merger with Skye to obtain a Nasdaq listing. The company previously attempted a similar transaction…